Billboard rules baffles DDMAC

Share this article:
“How does the FDA regard signage or billboards advertising pharmaceutical products that are prominently displayed at ballparks and other sports stadiums, and which may be viewed by tens of thousands or even millions of sports fans at televised events? Does such signage come under FDA's authority ... ?” 

This intriguing question from the audience seemed to stump a panel of FDA staffers at the DTC National Conference in Washington in April.

After a pause, Division of Drug Marketing, Advertising, and Communications reviewer Kathryn Aikin spoke for the panel: “Honestly, I don't know the answer to that question. I'm not sure we've ever thought about it. But we'll discuss it back at the office.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...